1020719-62-3

Pirfenidone-d₅ is intended for use as an internal standard for the quantification of pirfenidone by GC- or LC-MS. Pirfenidone is an orally bioavailable pyridone derivative with antifibrotic, anti-inflammatory, and antioxidant activities. It inhibits TGF-β1-stimulated increases in collagen type I, fibronectin, and Hsp47 expression in A549 lung cancer cells in a concentration-dependent manner. Pirfenidone (300 mg/kg per day) inhibits fibrosis and inhibits increases in collagen content, fibrocyte pool size, and the levels of chemokines CCL2 and CCL12 in lung in a mouse model of pulmonary fibrosis induced by bleomycin . In a mouse model of non-alcoholic steatohepatitis (NASH), pirfenidone inhibits fibrosis and increases in hepatocyte apoptosis, lobular inflammation, and hepatic expression of the fibrosis-related genes Col1a1, Timp1, Tgfb1, Pdgfb, and Fgf2 when administered at a dose of 280 mg/kg but has no effect on steatosis. Pirfenidone also inhibits NADPH-dependent lipid peroxidation in sheep liver microsomes and scavenges hydroxyl radicals (IC₅₀s = ~6 and ~2.5 mM, respectively). Formulations containing pirfenidone have been used in the treatment of idiopathic pulmonary fibrosis.

Off-White Solid

A deuterated metabolite of Pirfenidone, a new drug to treat patients with kidney disease who have diabetes.

[1] CHIKARA KOMIYA. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.[J]. Scientific Reports, 2017: 44754. DOI: 10.1038/srep44754
[2] MINORU INOMATA. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis.[J]. Respiratory Research, 2014: 16. DOI: 10.1186/1465-9921-15-16
[3] H P MISRA  C R. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals.[J]. Molecular and Cellular Biochemistry, 2000, 204 1-2: 119-126. DOI: 10.1023/a:1007023532508
[4] KEIKO HISATOMI. Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells.[J]. BMC Pulmonary Medicine, 2012, 12: 24. DOI: 10.1186/1471-2466-12-24
[5] ANTJE MOELLER . The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?[J]. International Journal of Biochemistry & Cell Biology, 2008, 40 3: Pages 362-382. DOI: 10.1016/j.biocel.2007.08.011